Research Article
Usefulness of Patients-Reported Outcomes in Rheumatoid Arthritis Focus Group
Table 1
Characteristics of 135 patients with RA evaluated in the current study.
| | Characteristic | Mean ± SD |
| | Age | 53.63 ± 11.28 | | Age at onset | 40.5 ± 12.14 |
| | Characteristic | Median ± IQR |
| | Duration of the disease | 12 ± 14 | | Educational level (years) | 11 ± 10 | | Body mass index | 24.14 ± 5.69 | | Waist-hip ratio | 0.92 ± 0.09 | | Systolic blood pressure | 120 ± 20 | | Diastolic blood pressure | 70 ± 11 | | C-Reactive protein | 0.39 ± 1.06 | | DAS28 | 2.75 ± 1.30 | | HAQ | 0.99 ± 1.19 | | TJC physician | 2 ± 4 | | SJC physician | 2 ± 4 | | TJC patient | 7 ± 13 | | SJC patient | 4 ± 8 | | SDAI | 13.72 ± 14.45 | | CDAI | 13 ± 13.50 |
| | Variable | n/N (%) |
| |
Sociodemographic |
| | Female | 106/135 (78.5) | | Low educational level | 59/133 (44.4) | | Low socioeconomic status | 52/132 (39.4) | | Ever smoking | 50/134 (37.3) | | Household duties | 49/135 (36.3) |
| |
Clinical aspects |
| | Diabetes | 5/135 (3.7) | | Dyslipidemia | 28/135 (20.7) | | Hypertension | 56/135 (41.5) | | Thrombosis | 6/135 (4.4) | | Osteoporosis | 42/135 (31.1) | | Occlusive arterial disease | 3/135 (2.2) | | Cardiovascular disease | 63/135 (46.7) | | Abnormal body mass index | 61/133 (45.9) | | Abdominal obesity | 106/134 (79.1) | | Physical activity | 44/135 (32.6) |
| |
RA characteristics |
| | Typical morning stiffness | 100/134 (74.6) | | Duration disease > 10 years | 78/135 (57.9) | | Erosions | 71/108 (65.7) | | Nodules | 40/135 (29.6) | | EAMs | 47/135 (34.8) | | EAMs with CVD | 87/135 (64.4) | | Rheumatoid factor + | 106/124 (85.5) | | Anti CCP + | 58/70 (89.2) | | Methotrexate | 121/135 (89.6) | | DMARD | 128/135 (42.2) | | Antimalarials | 106/135 (78.5) | | Steroids | 122/135 (90.4) | | Biological agents | 57/135 (42.2) | | Alternative medicine | 73/130 (56.2) |
| |
Autoimmunity |
| | Systemic lupus erythematosus | 1/135 (0.7) | | Autoimmune thyroid disease | 13/135 (9.6) | | Sjögren's syndrome | 4/135 (3) | | Antiphospholipid syndrome | 2/135 (1.5) | | Vitiligo | 1/135 (0.7) | | Scleroderma | 1/135 (0.7) | | Polyautoimmunity | 19/135 (14.1) | | MAS | 3/135 (2.2) | | Familial autoimmunity FDR | 22/135 (16.3) | | Familial autoimmunity SDR | 5/135 (4.4) | | ANAs + | 63/99 (63.6) |
|
|
RA: rheumatoid arthritis; SD: standard deviation; IQR: interquartile range; DAS28: disease activity score; HAQ: health assessment questionnaire; TJC: tender joint count; SJC: swollen joint count; SDAI: simplified disease activity index; CDAI: clinical disease activity index; EAMs: extraarticular manifestations; CVD: cardiovascular disease; Anti-CCP: anticyclic citrullinated peptide; DMARD: disease modifying-antirheumatic drugs; MAS: multiple autoimmune syndrome; FDR: first degree relatives; SDR: secondary-degree relatives; ANAs: antinuclear antibodies.
|
